Govindan. MW de oncología 4ed

136

M A N U A L W A S H I N G T O N ® D E O N C O L O G Í A

Page DB, Postow MA, Callahan MK, et al. Immune modulation in cancer with antibodies. Ann Rev Med 2014;65:185–202. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremeli mumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013;31:616–622. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untrea ted metastatic melanoma. N Engl J Med 2011;364:2517–2526. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550–4557. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018;379:2108–2121. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–2454. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and ki netics of response with ipilimumab. J Clin Oncol 2012;30:2691–2697. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412–7420.

SAMPLE